Patents by Inventor Marie Momot

Marie Momot has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CyaA-carried polypeptide(s) and use to induce both therapeutic and prophylactic immune responses
    Patent number: 9902947
    Abstract: The invention is directed to means, based on CyaA-carried polypeptide(s), for use in the immunotherapeutic treatment of first determined pathological condition(s) diagnosed in a mammalian host by eliciting a T cell immune response against a first group of epitopes contained in said polypeptide(s) and in the prophylaxis against second determined pathological condition(s) in the same mammalian host by eliciting a T cell memory immune response against a second group of epitopes contained in said polypeptide(s), said immune responses being obtained after administration of said vector-carried polypeptide(s) into said host, wherein said prophylaxis against second determined pathological condition(s) is not observed when said second group of epitopes is not contained in said administered vector-carried polypeptide(s).
    Type: Grant
    Filed: January 24, 2012
    Date of Patent: February 27, 2018
    Assignee: GENTICEL
    Inventors: Michael Esquerré, Marie Momot, Anne Goubier, Yolande Misseri
  • CYAA-CARRIED POLYPEPTIDE(S) AND USE TO INDUCE BOTH THERAPEUTIC AND PROPHYLACTIC IMMUNE RESPONSES
    Publication number: 20140037670
    Abstract: The invention is directed to means, based on CyaA-carried polypeptide(s), for use in the immunotherapeutic treatment of first determined pathological condition(s) diagnosed in a mammalian host by eliciting a T cell immune response against a first group of epitopes contained in said polypeptide(s) and in the prophylaxis against second determined pathological condition(s) in the same mammalian host by eliciting a T cell memory immune response against a second group of epitopes contained in said polypeptide(s), said immune responses being obtained after administration of said vector-carried polypeptide(s) into said host, wherein said prophylaxis against second determined pathological condition(s) is not observed when said second group of epitopes is not contained in said administered vector-carried polypeptide(s).
    Type: Application
    Filed: January 24, 2012
    Publication date: February 6, 2014
    Applicant: GENTICEL
    Inventors: Michael EsquerrÉ, Marie Momot, Anne Goubier, Yolande Misseri